As the federal government shuts down following the failure of Congress to agree on how to fund the government (with healthcare standing out as a flashpoint), and after the Trump Administration instructed federal agencies to prepare reduction-in-force plans that would go beyond standard shutdown furloughs, other industry-specific news continues to break:
- Branded Pharmaceutical Tariffs
- Most-Favored-Nation Deal and a New Drug Pricing Proposal
- Section 232 Investigation into Medtech
- No SBIR/STTR Extension
Branded Pharmaceutical Tariffs
On September 25, President Trump announced on Truth Social that, starting just six days later, tariffs of 100% will apply to brand-name pharmaceuticals unless a company is actively building a plant in the U.S.
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released a statement on the potential for 100% tariffs on branded or patented…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
